vs
INTERPARFUMS INC（IPAR）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
INTERPARFUMS INC的季度营收约是Orthofix Medical Inc.的1.8倍（$386.2M vs $219.9M），INTERPARFUMS INC净利率更高（7.3% vs -1.0%，领先8.3%），INTERPARFUMS INC同比增速更快（6.8% vs 2.0%），INTERPARFUMS INC自由现金流更多（$145.0M vs $16.8M），过去两年INTERPARFUMS INC的营收复合增速更高（9.2% vs 8.0%）
Inter Parfums Inc是全球知名的高端香水企业，开发、生产并销售多款授权香水、身体护理及相关美妆产品，与多家顶级奢侈时尚生活方式品牌合作推出联名香氛系列，产品覆盖全球主要市场，通过百货、美妆专营店及官方电商渠道触达消费者。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
IPAR vs OFIX — 直观对比
营收规模更大
IPAR
是对方的1.8倍
$219.9M
营收增速更快
IPAR
高出4.9%
2.0%
净利率更高
IPAR
高出8.3%
-1.0%
自由现金流更多
IPAR
多$128.2M
$16.8M
两年增速更快
IPAR
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $386.2M | $219.9M |
| 净利润 | $28.1M | $-2.2M |
| 毛利率 | 61.5% | 71.1% |
| 营业利润率 | 7.1% | 0.2% |
| 净利率 | 7.3% | -1.0% |
| 营收同比 | 6.8% | 2.0% |
| 净利润同比 | 16.0% | 92.4% |
| 每股收益（稀释后） | $0.88 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IPAROFIX
| Q4 25 | $386.2M | $219.9M | ||
| Q3 25 | $429.6M | $205.6M | ||
| Q2 25 | $333.9M | $203.1M | ||
| Q1 25 | $338.8M | $193.6M | ||
| Q4 24 | $361.5M | $215.7M | ||
| Q3 24 | $424.6M | $196.6M | ||
| Q2 24 | $342.2M | $198.6M | ||
| Q1 24 | $324.0M | $188.6M |
净利润IPAROFIX
| Q4 25 | $28.1M | $-2.2M | ||
| Q3 25 | $65.8M | $-22.8M | ||
| Q2 25 | $32.0M | $-14.1M | ||
| Q1 25 | $42.5M | $-53.1M | ||
| Q4 24 | $24.2M | $-29.1M | ||
| Q3 24 | $62.3M | $-27.4M | ||
| Q2 24 | $36.8M | $-33.4M | ||
| Q1 24 | $41.0M | $-36.0M |
毛利率IPAROFIX
| Q4 25 | 61.5% | 71.1% | ||
| Q3 25 | 63.5% | 72.2% | ||
| Q2 25 | 66.2% | 68.7% | ||
| Q1 25 | 63.7% | 62.8% | ||
| Q4 24 | 64.5% | 69.0% | ||
| Q3 24 | 63.9% | 68.7% | ||
| Q2 24 | 64.5% | 67.8% | ||
| Q1 24 | 62.5% | 67.5% |
营业利润率IPAROFIX
| Q4 25 | 7.1% | 0.2% | ||
| Q3 25 | 25.3% | -8.3% | ||
| Q2 25 | 17.7% | -7.9% | ||
| Q1 25 | 22.2% | -25.2% | ||
| Q4 24 | 10.0% | -5.3% | ||
| Q3 24 | 25.0% | -9.6% | ||
| Q2 24 | 18.9% | -12.5% | ||
| Q1 24 | 21.0% | -15.6% |
净利率IPAROFIX
| Q4 25 | 7.3% | -1.0% | ||
| Q3 25 | 15.3% | -11.1% | ||
| Q2 25 | 9.6% | -6.9% | ||
| Q1 25 | 12.5% | -27.4% | ||
| Q4 24 | 6.7% | -13.5% | ||
| Q3 24 | 14.7% | -13.9% | ||
| Q2 24 | 10.8% | -16.8% | ||
| Q1 24 | 12.7% | -19.1% |
每股收益（稀释后）IPAROFIX
| Q4 25 | $0.88 | $-0.05 | ||
| Q3 25 | $2.05 | $-0.57 | ||
| Q2 25 | $0.99 | $-0.36 | ||
| Q1 25 | $1.32 | $-1.35 | ||
| Q4 24 | $0.78 | $-0.76 | ||
| Q3 24 | $1.93 | $-0.71 | ||
| Q2 24 | $1.14 | $-0.88 | ||
| Q1 24 | $1.27 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $137.1M | $82.0M |
| 总债务越低越好 | $176.0M | — |
| 股东权益账面价值 | $880.7M | $450.0M |
| 总资产 | $1.6B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.20× | — |
8季度趋势，按日历期对齐
现金及短期投资IPAROFIX
| Q4 25 | $137.1M | $82.0M | ||
| Q3 25 | $77.5M | $62.9M | ||
| Q2 25 | $53.9M | $65.6M | ||
| Q1 25 | $75.3M | $58.0M | ||
| Q4 24 | $109.3M | $83.2M | ||
| Q3 24 | $78.8M | $30.1M | ||
| Q2 24 | $37.7M | $26.4M | ||
| Q1 24 | $76.1M | $27.0M |
总债务IPAROFIX
| Q4 25 | $176.0M | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | $157.3M | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益IPAROFIX
| Q4 25 | $880.7M | $450.0M | ||
| Q3 25 | $870.9M | $442.5M | ||
| Q2 25 | $839.4M | $458.3M | ||
| Q1 25 | $788.6M | $458.3M | ||
| Q4 24 | $744.9M | $503.1M | ||
| Q3 24 | $778.5M | $525.9M | ||
| Q2 24 | $717.1M | $546.0M | ||
| Q1 24 | $708.1M | $570.3M |
总资产IPAROFIX
| Q4 25 | $1.6B | $850.6M | ||
| Q3 25 | $1.6B | $832.6M | ||
| Q2 25 | $1.6B | $837.2M | ||
| Q1 25 | $1.4B | $823.1M | ||
| Q4 24 | $1.4B | $893.3M | ||
| Q3 24 | $1.5B | $867.9M | ||
| Q2 24 | $1.4B | $882.0M | ||
| Q1 24 | $1.3B | $906.0M |
负债/权益比IPAROFIX
| Q4 25 | 0.20× | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | 0.21× | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $146.5M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $145.0M | $16.8M |
| 自由现金流率自由现金流/营收 | 37.5% | 7.6% |
| 资本支出强度资本支出/营收 | 0.4% | 4.9% |
| 现金转化率经营现金流/净利润 | 5.21× | — |
| 过去12个月自由现金流最近4个季度 | $190.5M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流IPAROFIX
| Q4 25 | $146.5M | $27.7M | ||
| Q3 25 | $63.9M | $12.4M | ||
| Q2 25 | $11.9M | $11.6M | ||
| Q1 25 | $-7.4M | $-18.4M | ||
| Q4 24 | $138.0M | $23.7M | ||
| Q3 24 | $76.1M | $11.7M | ||
| Q2 24 | $25.5M | $9.0M | ||
| Q1 24 | $-52.0M | $-18.6M |
自由现金流IPAROFIX
| Q4 25 | $145.0M | $16.8M | ||
| Q3 25 | $57.6M | $2.5M | ||
| Q2 25 | $-3.3M | $4.5M | ||
| Q1 25 | $-8.8M | $-25.1M | ||
| Q4 24 | $136.1M | $15.2M | ||
| Q3 24 | $75.4M | $6.3M | ||
| Q2 24 | $24.4M | $-360.0K | ||
| Q1 24 | $-53.0M | $-29.1M |
自由现金流率IPAROFIX
| Q4 25 | 37.5% | 7.6% | ||
| Q3 25 | 13.4% | 1.2% | ||
| Q2 25 | -1.0% | 2.2% | ||
| Q1 25 | -2.6% | -13.0% | ||
| Q4 24 | 37.7% | 7.0% | ||
| Q3 24 | 17.8% | 3.2% | ||
| Q2 24 | 7.1% | -0.2% | ||
| Q1 24 | -16.4% | -15.4% |
资本支出强度IPAROFIX
| Q4 25 | 0.4% | 4.9% | ||
| Q3 25 | 1.5% | 4.8% | ||
| Q2 25 | 4.5% | 3.5% | ||
| Q1 25 | 0.4% | 3.5% | ||
| Q4 24 | 0.5% | 4.0% | ||
| Q3 24 | 0.2% | 2.7% | ||
| Q2 24 | 0.3% | 4.7% | ||
| Q1 24 | 0.3% | 5.6% |
现金转化率IPAROFIX
| Q4 25 | 5.21× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 0.37× | — | ||
| Q1 25 | -0.17× | — | ||
| Q4 24 | 5.69× | — | ||
| Q3 24 | 1.22× | — | ||
| Q2 24 | 0.69× | — | ||
| Q1 24 | -1.27× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IPAR
| European Based Operations | $232.7M | 60% |
| United States Based Operations | $155.2M | 40% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
